Profound Medical (PROF) Fundamental Analysis: Revenue, Earnings & Valuation

0.72 / 10

Underperform

Fundamental rating is Underperform with a 0.7/10 score. Profit‑MV and Net‑profit/Total‑profit show modest strength, while Cash‑MV, ROA and margins are deeply negative, indicating poor quality and limited upside.

Analysis Checks(3/10)

Revenue-MV

Value-1.95

Score2/3

Weight-6.07%

1M Return1.21%

ROA (%)

Value-57.64

Score0/3

Weight21.12%

1M Return-6.58%

Net cash flow from operating activities / Operating revenue (%)

Value-237.34

Score0/3

Weight21.16%

1M Return-6.63%

Profit-MV

Value0.66

Score2/3

Weight-18.05%

1M Return3.09%

Annualized net profit margin on total assets (%)

Value-57.64

Score0/3

Weight21.12%

1M Return-6.58%

EBIT / Total operating revenue (%)

Value-269.52

Score1/3

Weight3.55%

1M Return-0.83%

Asset-MV

Value-0.55

Score0/3

Weight15.71%

1M Return-3.44%

Net profit / Total operating revenue (%)

Value-264.44

Score0/3

Weight21.55%

1M Return-6.68%

Cash-MV

Value0.02

Score1/3

Weight17.12%

1M Return-4.16%

Net profit / Total profit (%)

Value100.60

Score2/3

Weight2.80%

1M Return-0.54%

Is PROF undervalued or overvalued?

PROF scores 0.72/10 on fundamentals and holds a Premium valuation at present. Backed by its -67.12% ROE, -264.44% net margin, -5.52 P/E ratio, 3.54 P/B ratio, and -25.89% earnings growth, these metrics solidify its Underperform investment rating.